ProKidney (NASDAQ:PROK) Stock Price Up 6.2% – Should You Buy?

ProKidney Corp. (NASDAQ:PROK) traded up 6.2% during trading on Tuesday . The company traded as high as $1.81 and last traded at $1.80. 183,438 shares were traded during mid-day trading, a decline of 73% from the average session volume of 685,976 shares. The stock had previously closed at $1.69.

Analyst Upgrades and Downgrades

PROK has been the subject of a number of research reports. Bank of America cut their target price on shares of ProKidney from $4.00 to $3.00 and set a “neutral” rating for the company in a research report on Wednesday, September 4th. Guggenheim initiated coverage on ProKidney in a research report on Tuesday, September 10th. They set a “buy” rating and a $6.00 price objective for the company. Finally, JPMorgan Chase & Co. assumed coverage on ProKidney in a research report on Monday, September 30th. They set a “neutral” rating for the company. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, ProKidney currently has an average rating of “Hold” and an average price target of $4.50.

ProKidney Price Performance

The stock has a market cap of $508.83 million, a price-to-earnings ratio of -3.17 and a beta of 1.27. The stock’s 50-day moving average is $1.83 and its 200-day moving average is $2.12.

ProKidney (NASDAQ:PROK) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.14). Analysts predict that ProKidney Corp. will post -0.57 EPS for the current fiscal year.

Institutional Trading of ProKidney

A number of hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC purchased a new position in shares of ProKidney during the 2nd quarter worth about $50,000. XTX Topco Ltd acquired a new position in ProKidney during the third quarter worth approximately $41,000. Intech Investment Management LLC purchased a new position in ProKidney during the third quarter worth approximately $46,000. The Manufacturers Life Insurance Company acquired a new position in shares of ProKidney in the 2nd quarter valued at $60,000. Finally, Castleview Partners LLC purchased a new stake in shares of ProKidney during the 3rd quarter valued at $63,000. 51.59% of the stock is owned by institutional investors and hedge funds.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.